Cohera Medical’s Novel Sealant Picked For FDA 'Expedited Access'
This article was originally published in The Gray Sheet
FDA launched its new Expedited Access Pathway in April, and Cohera Medical is now the first company to announce participation for its Sylys Surgical Sealant. Under the program, Cohera hopes to use an interim trial analysis to accelerate the product's path to market.
You may also be interested in...
But the April 29 updated draft of the broad-based House reform package for medical innovation is missing some significant items floated earlier this year, including a Medicare breakthrough device program, a revamp of diagnostics regulations and device supply-chain security reform.
Celltrion has accelerated the development of its antiviral treatment for COVID-19 and aims to launch a rapid self-testing kit that could provide results within 15-20 minutes. The Korean firm also plans to develop a ‘super antibody’ to prepare for potential future pandemic situations.
Paracetamol, acetylcysteine and loperamide among list of OTC drugs deemed "essential" by Spain in the fight against coronavirus.